Dr. Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Medical Director (Oncology) of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong. Dr. Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology and Sarcoma Medical Oncology. He was elected as a Fellow of ASCO (FASCO) in 2024.
In recent years, Dr. Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).
Dr. Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee (IAC) and the Asia-Pacific Regional Council of ASCO. After completing his role as the Chair of the IAC of ASCO (2024-25), He currently serves as the Immediate Past Chair (2025-2026). He has also served in the Membership, Education and Communications Committees of the IASLC. He was selected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. Dr. Loong is a current Steering Committee member of the Lung Cancer Policy Network (LCPN). In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.
